site stats

Gemini therapeutics press release

WebApr 11, 2024 · Source: Gemini Therapeutics. Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-related adverse …

8-K - SEC

WebNov 13, 2024 · CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment … WebDec 29, 2024 · Following the reverse stock split and closing of the merger, there will be approximately 17 million shares of the combined company's common stock outstanding with prior Disc shareholders owning ... bowling green airport flights https://roschi.net

425 - sec.gov

WebJun 22, 2024 · Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. ... press releases ... WebMar 10, 2024 · Gemini reported a net loss of $71.9 million for the full year 2024 compared to $40.8 million for the same period in 2024. Research and development expenses were $48.7 million and $28.2 million for ... WebDec 29, 2024 · Concurrent with the closing of the merger, Disc completed a financing of $53.5 million from a syndicate of healthcare investors led by Access Biotechnology and including OrbiMed, Atlas Venture ... bowling green approved premises phone number

2024-10-05 NDAQ:IRON Press Release Disc Medicine Inc.

Category:Gemini Therapeutics Announces Corporate Restructuring …

Tags:Gemini therapeutics press release

Gemini therapeutics press release

Gemini Therapeutics Provides Corporate Update - Feb 28, 2024

WebDec 29, 2024 · Disc Medicine Announces Completion of Merger with Gemini Therapeutics. The combined company will operate as Disc Medicine and will trade on the Nasdaq … WebOct 5, 2024 · Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-rel ...

Gemini therapeutics press release

Did you know?

WebMar 10, 2024 · The following information was filed by Gemini Therapeutics, Inc. De (GMTX) on Thursday, March 10, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. WebOn January 10, 2024, the Company issued a press release entitled “Gemini Therapeutics Provides GEM103 Program Update.” The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities …

WebCompleted reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2024 with approximately $194.6 million in cash and cash… read more Disc … WebAug 10, 2024 · Gemini Therapeutics is a clinical-stage precision medicine company previously focused on developing novel therapeutic compounds to treat genetically …

WebMar 1, 2024 · Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), announced a series of corporate updates Monday. Among these is a corporate restructuring that will see a drastic 80% of the company's workforce laid off. ... In the press release, … WebOct 5, 2024 · Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD). GEM103 has the potential …

WebDec 29, 2024 · Concurrent with the closing of the merger, Disc completed a financing of $53.5 million from a syndicate of healthcare investors led by Access Biotechnology and …

WebSep 1, 2024 · Gemini Therapeutics, Inc. (Nasdaq - GMTX) Under the terms of the agreement, Gemini will merge with Disc Medicine, Inc. (“Disc”). Pre-merger Gemini shareholders are expected to own ... bowling green and new mexico stateWebNov 23, 2024 · Find the latest press releases from Gemini Therapeutics, Inc. Common Stock (GMTX) at Nasdaq.com. bowling green alumni directoryWebAug 10, 2024 · Gemini Therapeutics, Inc. will be renamed "Disc Medicine, Inc." and the corporate headquarters will be located in Watertown, MA. ... Certain statements in this … gummy bear earringsWebMay 31, 2024 · NEW YORK, May 31, 2024 /PRNewswire/ -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ... bowling green airport kyWebMar 1, 2024 · Gemini Therapeutics, a clinical-stage biopharma company dedicated to developing treatments for genetically defined age-related macular degeneration (AMD), … gummy bear duct tapeWebNov 12, 2024 · Gemini Therapeutics, Inc. today announced that Raj Maturi, M.D., will present a poster at the 2024 Annual Meeting of the American Academy of … gummy bear dutchWebCompleted reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2024 with approximately $194.6 million in cash and cash… read more Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA) gummy bear earrape